Jerome J. Schentag - Concepedia

Author

Jerome J. Schentag

University at Buffalo, State University of New York ORCID

Also Known As

Hugh H. Tilson, J J Schentag, J Schentag, J. J. SCHENTAG, J. J. Schentag, J. Schentag, J.J. Schentag, JEROME J. SCHENTAG, JEROME SCHENTAG, Janelle Schentag

278

Publications

18.8K

Citations

H-Index

170

Concepts

All Affiliations

University at Buffalo, State University of New York Millard Fillmore Suburban Hospital Kaleida Health

About

Jerome J. Schentag is an author at University at Buffalo, State University of New York specializing in medicine, pharmacology, and antimicrobial resistance.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	50	112	8.8K
2	Health Sciences	25	29	3.5K
3	Engineering	2	2	89
4	Natural Sciences	1	1	44
5	Nursing	1	1	22

Jerome J. Schentag

165

Publications

14.5K

Citations

H-Index

Page 1

	Year	Citations
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients Alan Forrest, David E. Nix, Charles H. Ballow, Antimicrobial Agents and Chemotherapy	1993	1.1K
Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia George Sakoulas, Pamela A. Moise-Broder, Jerome J. Schentag, Journal of Clinical Microbiology	2004	834
Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections Pamela A. Moise-Broder, Alan Forrest, Mary C. Birmingham, Clinical Pharmacokinetics Antimicrobial SusceptibilityHealth SciencesAntibioticsOther AntimicrobialsMedicine	2004	744
Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy Jennifer Thomas, Alan Forrest, Sujata M. Bhavnani, Antimicrobial Agents and Chemotherapy	1998	512
Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group Mitchell P. Fink, David R. Snydman, Michael S. Niederman, Antimicrobial Agents and Chemotherapy	1994	460
Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections Peggy S. McKinnon, Joseph A. Paladino, Jerome J. Schentag International Journal of Antimicrobial Agents Serious Bacterial InfectionsMinimum Inhibitory ConcentrationAntimicrobial SusceptibilityAntimicrobial StewardshipMedicine	2008	455
Linezolid for the Treatment of Multidrug‐Resistant, Gram‐Positive Infections: Experience from a Compassionate‐Use Program Mary C. Birmingham, Craig R. Rayner, Alison Meagher, Clinical Infectious Diseases Antimicrobial ChemotherapyDrug ResistanceAntimicrobial StewardshipHealthcare-associated InfectionCompassionate-use Program	2003	426
Accessory Gene Regulator Group II Polymorphism in Methicillin-Resistant Staphylococcus aureus Is Predictive of Failure of Vancomycin Therapy Pamela A. Moise-Broder, George Sakoulas, George M. Eliopoulos, Clinical Infectious Diseases Vancomycin TherapyVancomycin Selective PressureAntimicrobial SusceptibilityHealth SciencesAntibiotics	2004	330
Clinical Pharmacodynamics of Linezolid in Seriously Ill Patients Treated in a Compassionate Use Programme Craig R. Rayner, Alan Forrest, Alison Meagher, Clinical Pharmacokinetics Clinical PharmacodynamicsMedicineCompassionate Use ProgrammePharmacotherapyAntimicrobial Chemotherapy	2003	303
The Burden of Staphylococcus aureus Infections on Hospitals in the United States Gary A. Noskin, Robert J. Rubin, Jerome J. Schentag, Archives of Internal Medicine	2005	297

Page 1